Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 (CLDN1) ADCs in solid tumors

by | 12 Nov Tue | English

Building on its co-lead investments in Alentis Therapeutics’ Series B (2021) and Series C (2023) rounds, Jeito’s renewed commitment demonstrates its strategy of supporting promising portfolio companies through key value-creation milestones. Financing will advance...

Jeito Capital announces acquisition of portfolio company HI-Bio™ by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 billion; Biogen to strengthen portfolio to help patients with severe immune-mediated disease

by | 22 May Wed | English

Biogen Inc. (Nasdaq: BIIB) to acquire HI-Bio™ for a total consideration of up to $1.8 billion which illustrates that HI-Bio™, with Jeito’s ongoing strategic and operational support, has achieved significant progress in its late-stage clinical programs. This...